Blueprint Medicines Corp ASCO 2019 Analyst and Investor Reception Transcript
All right. So on behalf of all the employees at Blueprint Medicines, I want thank you for joining us tonight and taking time out of an incredibly busy schedule, I'm sure, for all of you. I know there are multiple events tonight. So we really appreciate you spending a little bit of time with us.
As always we'll be making forward-looking statements, and so we'll refer you to our SEC filing documents or our website. And we disclaim any obligation to update any of those forward-looking statements.
So agenda-wise, I'm going to start off with a quick overview of Blueprint Medicines. But as I look around at the faces in the crowd, this is a group that is very well versed in our overall portfolio, so I'll try to keep that brief. And then I'm going to turn it over to Professor Benjamin Besse from Gustave Roussy Cancer Center, who's going to walk through both the BLU-667 lung data as well as the medullary thyroid data. And then Andy Boral will wrap things up with pulling all of that together and adding a bit more
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
